With mounting calls for U.S. Sen. Bob Menendez to resign, the pharmaceutical industry could lose one of its increasingly rare Democratic allies.

Svetlana Mojsov, on the discovery of GLP-1: “This is not about me getting prizes. It’s about me actually not being erased from the scientific literature.”

There is no evidence to suggest that the current regulatory framework inhibits biosimilar uptake.

If U.S. lawmakers are unable to prevent a government shutdown by Oct. 1, the FDA will have to furlough almost one-fifth of its staff.

"I just worry about the precedent that, once again, the big institutions get this advantage over private practices.”

This was supposed to be the year the biotech industry recovered from its ongoing slump, but that simply hasn’t happened.

The XBI biotech index has fallen more than 10% in 2023, while the S&P 500 rose about 13%. But there’s optimism heading into the last quarter of the year.

Yale and one of its professors agreed to settle allegations that they wrongly withheld patent royalties for ketamine-related inventions.

FDA inspectors issued a report detailing quality control lapses at Novo Nordisk's main factory in North America as early as May last year.

Eli Lilly sued several compounding pharmacies, spas, and wellness centers for selling unapproved versions of Mounjaro.

"The idea here is you can still get a patent but it wouldn’t be implemented as a monopoly on a drug or vaccine or other medical technology."

A company that makes a crucial TB test has agreed to sell its product at cost for use in poor countries.

Chamber and government lawyers sparred over whether drugmakers have enough say in Medicare’s drug price-negotiation program.

A House committee took a first step toward legislation to fix hospital drug shortages, but do not expect a new law soon.

Ian Wilmut, the British scientist behind the first-ever cloning of a mammal, died Sept. 10, leaving behind a twofold legacy.

A HHS deal for a Regeneron drug marks the first time the administration has directly used its leverage to challenge list prices.

The leading decongestant used by millions of Americans is no better than a dummy pill, FDA scientiific advisers concluded.

Neurocrine Biosciences announced on Tuesday that an experimental drug for congenital adrenal hyperplasia succeeded in a late-stage trial.

The FDA issued new guidelines clarifying the way they plan to evaluate medical devices that go through the controversial 510(k) pathway.

AstraZeneca appeared to play down speculation about CEO Pascal Soriot after a U.K. tabloid report that he was considering leaving.

President Biden’s nominee to lead NIH will get a hearing next month, perhaps thanks to a drug-pricing deal.

Novartis is changing the name — and the guiding strategy — of its research and development hub in Cambridge, Mass.

Oncologists in Philadelphia are alleging Jefferson Health system is violating federal antitrust and kickback laws by creating a “concerted campaign to eliminate” the group’s “presence in the oncology marketplace.”

“Maybe somebody is not yet ready for recovery, but that does not mean that they don’t deserve safety and peace and rest.”

Vaccine contracts show South Africa was “bullied” into one-sided deals with Covid-19 shot suppliers.

“If we're going to do it, let's make sure we're leveraging things that Amazon does really well, which is connecting buyers and sellers,” said Nworah Ayogu, Amazon Clinic’s chief medical…